We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Read MoreHide Full Article
Key Takeaways
Fresenius Medical Care is focusing its China strategy on advanced dialysis and critical-care technologies.
FMS will end 4008A production and sales and exit China's peritoneal dialysis business.
FMS expects about 110M euros in one-time costs, with no significant impact on future China revenue outlook.
Fresenius Medical Care AG & Co. (FMS - Free Report) recently refined its China commercial strategy to focus on areas offering stronger long-term growth potential and strengthen its position in the country’s dialysis market. The company plans to prioritize advanced in-center dialysis and critical-care technologies while streamlining parts of its existing portfolio and adopting a more focused go-to-market approach.
Per management, China remains an important market for Fresenius Medical Care’s Care Enablement business. As the market evolves, the company is refining its portfolio to focus on areas offering the greatest value to patients and customers.
Joe Turk, CEO of FMS’ Care Enablement operating segment, believes the refined portfolio and strategy will strengthen its ability to compete and grow in China. The company remains committed to the market and plans to leverage its local manufacturing footprint and China Design Center to support profitable growth.
FMS Stock Trend Following the News
FMS stock has gained 1.1% since the announcement on Friday. Year to date, shares of the company have lost 3.7% compared with the industry’s 3.9% decline. However, the S&P 500 increased 11.8% in the same time frame.
The portfolio realignment could support FMS’ long-term margin profile by shifting its China business toward areas with better utilization and commercial returns. Greater localization may also help the company respond more efficiently to changing customer needs and strengthen its operating leverage in the region. While restructuring costs could pressure near-term earnings, the actions may improve the quality and sustainability of future growth.
FMS currently has a market capitalization of $12.19 billion.
Image Source: Zacks Investment Research
More on Fresenius Medical Care’s China Strategy
China has been an important market for Fresenius Medical Care for more than two decades and contributes approximately 6-7% of the company’s Care Enablement operating segment revenues. FMS sees further potential in the market as the prevalence of chronic kidney disease rises, dialysis care expands and demand for advanced treatment technologies increases.
Under the refined portfolio strategy, Fresenius Medical Care will place greater emphasis on innovative technologies for in-center dialysis and critical care. Main products include the high-volume hemodiafiltration-enabled 5008S CAREsystem, multiFiltratePRO and other advanced dialysis technologies. The company intends to support these offerings through its local manufacturing capabilities and China Design Center.
As part of the portfolio optimization, Fresenius Medical Care will discontinue local production and sales of the 4008A hemodialysis system and exit its China peritoneal dialysis business while continuing to meet existing obligations in the market. The company has also strengthened its local leadership with the appointment of Rex Liu as market general manager.
The portfolio actions are expected to result in approximately €110 million of one-time costs, primarily related to impairment charges, scrappage and termination costs. The costs are expected to be recognized as a special item in the third quarter of 2026. FMS does not expect the portfolio changes to significantly affect the future revenue outlook for its China Care Enablement business.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global dialysis equipment market is estimated to reach $9.3 billion in 2026 and is projected to expand at a 7.1% CAGR through 2035.
Factors such as the rising prevalence of chronic kidney disease, end-stage renal disease, diabetes and hypertension, increasing demand for kidney replacement therapy, improving healthcare infrastructure and growing adoption of advanced dialysis technologies are supporting market growth.
Other News
In July, Fresenius Medical Care announced BEACON-US, a U.S. research initiative evaluating high-volume hemodiafiltration (HVHDF) in routine clinical practice across diverse patient populations. Early observations show improved dialysis adequacy, higher convective volumes without longer treatment times and 40% fewer muscle cramps. The initiative expands real-world evidence supporting HVHDF as the company accelerates its U.S. rollout.
Fresenius Medical Care launched TherapyWise, a cloud-based analytics solution within its FDA-cleared NxView 4.0 platform for the NxStage System One. Designed for hospital ICU settings, the software aggregates kidney replacement therapy data to identify trends in treatment delivery, workflow interruptions and alarm frequency, helping healthcare providers improve program oversight and operational efficiency.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
View the Zacks #1 Rank List
Image: Bigstock
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Key Takeaways
Fresenius Medical Care AG & Co. (FMS - Free Report) recently refined its China commercial strategy to focus on areas offering stronger long-term growth potential and strengthen its position in the country’s dialysis market. The company plans to prioritize advanced in-center dialysis and critical-care technologies while streamlining parts of its existing portfolio and adopting a more focused go-to-market approach.
Per management, China remains an important market for Fresenius Medical Care’s Care Enablement business. As the market evolves, the company is refining its portfolio to focus on areas offering the greatest value to patients and customers.
Joe Turk, CEO of FMS’ Care Enablement operating segment, believes the refined portfolio and strategy will strengthen its ability to compete and grow in China. The company remains committed to the market and plans to leverage its local manufacturing footprint and China Design Center to support profitable growth.
FMS Stock Trend Following the News
FMS stock has gained 1.1% since the announcement on Friday. Year to date, shares of the company have lost 3.7% compared with the industry’s 3.9% decline. However, the S&P 500 increased 11.8% in the same time frame.
The portfolio realignment could support FMS’ long-term margin profile by shifting its China business toward areas with better utilization and commercial returns. Greater localization may also help the company respond more efficiently to changing customer needs and strengthen its operating leverage in the region. While restructuring costs could pressure near-term earnings, the actions may improve the quality and sustainability of future growth.
FMS currently has a market capitalization of $12.19 billion.
Image Source: Zacks Investment Research
More on Fresenius Medical Care’s China Strategy
China has been an important market for Fresenius Medical Care for more than two decades and contributes approximately 6-7% of the company’s Care Enablement operating segment revenues. FMS sees further potential in the market as the prevalence of chronic kidney disease rises, dialysis care expands and demand for advanced treatment technologies increases.
Under the refined portfolio strategy, Fresenius Medical Care will place greater emphasis on innovative technologies for in-center dialysis and critical care. Main products include the high-volume hemodiafiltration-enabled 5008S CAREsystem, multiFiltratePRO and other advanced dialysis technologies. The company intends to support these offerings through its local manufacturing capabilities and China Design Center.
As part of the portfolio optimization, Fresenius Medical Care will discontinue local production and sales of the 4008A hemodialysis system and exit its China peritoneal dialysis business while continuing to meet existing obligations in the market. The company has also strengthened its local leadership with the appointment of Rex Liu as market general manager.
The portfolio actions are expected to result in approximately €110 million of one-time costs, primarily related to impairment charges, scrappage and termination costs. The costs are expected to be recognized as a special item in the third quarter of 2026. FMS does not expect the portfolio changes to significantly affect the future revenue outlook for its China Care Enablement business.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global dialysis equipment market is estimated to reach $9.3 billion in 2026 and is projected to expand at a 7.1% CAGR through 2035.
Factors such as the rising prevalence of chronic kidney disease, end-stage renal disease, diabetes and hypertension, increasing demand for kidney replacement therapy, improving healthcare infrastructure and growing adoption of advanced dialysis technologies are supporting market growth.
Other News
In July, Fresenius Medical Care announced BEACON-US, a U.S. research initiative evaluating high-volume hemodiafiltration (HVHDF) in routine clinical practice across diverse patient populations. Early observations show improved dialysis adequacy, higher convective volumes without longer treatment times and 40% fewer muscle cramps. The initiative expands real-world evidence supporting HVHDF as the company accelerates its U.S. rollout.
Fresenius Medical Care launched TherapyWise, a cloud-based analytics solution within its FDA-cleared NxView 4.0 platform for the NxStage System One. Designed for hospital ICU settings, the software aggregates kidney replacement therapy data to identify trends in treatment delivery, workflow interruptions and alarm frequency, helping healthcare providers improve program oversight and operational efficiency.
Fresenius Medical Care AG & Co. KGaA Price
Fresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote
FMS’ Zacks Rank & Key Picks
Currently, FMS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.